Alle Studien
RekrutierungPHASE3INTERVENTIONELL

Study of Olverembatinib (HQP1351) in Patients With CML-CP

This research study is investigating a new medication called olverembatinib for patients with Chronic Myeloid Leukemia (CML) in its chronic phase (CML-CP). The study has two main parts. One part compares how well olverembatinib works and its safety against an approved medicine called bosutinib. The other part specifically looks at olverembatinib in patients who have a particular genetic change in their CML, known as the T315I mutation. The aim is to see if olverembatinib is a safe and effective new treatment option for people living with CML-CP, especially for those who might not have other good treatment choices.

Auf einen Blick

Status
Rekrutierung
Phase
PHASE3
Sponsor
Ascentage Pharma Group Inc.
Einschreibeziel
333
Starten
05 Feb 2024
Geschätzte Fertigstellung
10 Jul 2028

Worum geht es in dieser Studie?

This research study is about finding new and better ways to treat a type of blood cancer called Chronic Myeloid Leukemia (CML). Specifically, it focuses on CML in its early, chronic phase (CML-CP). For people with CML-CP, treatments often involve medicines that target the cancer cells. However, sometimes these treatments stop working, or patients develop specific changes in their cancer cells that make current medicines less effective.

The study has two main goals. The first part compares a new, experimental medicine called olverembatinib with a medicine that's already approved and used, called bosutinib. This is to see which medicine works better and is safer for people with CML-CP who have already tried at least two other similar treatments. The second part of the study looks at olverembatinib on its own, for people with CML-CP who have a specific genetic change (called a T315I mutation) in their cancer cells. This mutation can make some CML medicines less effective, so finding new options is very important.

The overall aim of this study is to gather information that will help doctors understand if olverembatinib could be a useful new treatment option for people with CML-CP, especially for those who need more choices. If the study shows that olverembatinib is safe and effective, it could become available to more patients in the future.

Wichtige Erkenntnisse

  • The study explores a new CML medicine called olverembatinib.
  • It aims to find better treatments for CML, especially when other medicines haven't worked or for specific genetic changes.
  • Participation involves taking medication and attending regular check-ups.
  • There are potential benefits and risks, which your doctor will explain fully.
  • You can stop participating in the study at any time without affecting your normal care.

Wer könnte berechtigt sein?

To join this study, you need to be at least 18 years old and have a diagnosis of Chronic Myeloid Leukemia in its chronic phase (CML-CP). For the first part of the study (comparing olverembatinib with bosutinib), you must have already tried at least two other similar CML medicines. For the second part (for people with a specific genetic change), you need to have the T315I mutation and have tried at least one other CML medicine, without other good treatment options available.

Your general health also needs to be good enough to take part. This means your body's organs should be working properly, and you should be able to carry out most of your usual daily activities without too much difficulty. A doctor will check these things to make sure the study is safe for you.

However, there are some reasons why you might not be able to join. For example, if you have a certain genetic change (T315I or V299L) *before* starting treatment in the comparison part of the study. You also can't join if you have an active infection, problems with your gut that might affect how the medicine works, or if you've had a bad reaction to the study drugs before. Pregnant or breastfeeding women cannot participate.

Könnte diese Studie für Sie geeignet sein?

Beantworten Sie diese kurzen Fragen, um zu sehen, ob Sie möglicherweise berechtigt sind. Dies ist nur ein Leitfaden – das Forschungsteam trifft die endgültige Entscheidung.

  1. Sind Sie 18 Jahre alt oder älter?
  2. Have you been diagnosed with CML-CP (Chronic Myeloid Leukemia - Chronic Phase)?
  3. Have you already tried at least two other CML medicines (or one if you have the T315I gene change)?
  4. Are you generally well enough to do most daily activities?
  5. Sind Sie NICHT schwanger oder stillen?
Beantworten Sie jede Frage, um Ihr Ergebnis zu sehen.

Was beinhaltet die Teilnahme?

If you decide to take part in this study, you will be given either the new medicine (olverembatinib) or an existing one (bosutinib) as tablets. The study will involve regular visits to the hospital or clinic where doctors and nurses will monitor your health, check how you are responding to the treatment, and look for any side effects. These checks will include blood tests, physical examinations, and possibly other tests.

For the first part of the study, you won't know whether you're getting olverembatinib or bosutinib, but both are active treatments. For the second part, everyone receives olverembatinib. If you are in the comparison part and your current treatment stops working, you might have the option to switch to olverembatinib later on. The total duration of your participation, including treatment and follow-up, will be explained in detail by the study team, as it can vary.

Potenzielle Risiken und Vorteile

Taking part in any clinical study has potential benefits and risks. A potential benefit of joining this study is that you might receive a new medicine that could be more effective for your CML, especially if other treatments haven't worked well for you, or if you have a specific genetic change. However, there's no guarantee that the new medicine will help you, or that it will be better than existing treatments. Potential risks include experiencing side effects from the study medicines, which will be carefully monitored by the study team. You will be given full details of known side effects. It's very important to remember that joining this study is completely your choice, and you can leave the study at any time, for any reason, without it affecting your usual medical care.

Standorte (163)

  • Ascentage Investigative Site #1044
    Verifizierte Postleitzahl
    Birmingham, Vereinigte Staaten· Rekrutierung
  • Ascentage Investigative Site #1112
    Verifizierte Postleitzahl
    Anchorage, Vereinigte Staaten· Rekrutierung
  • Ascentage Investigative Site #1111
    Verifizierte Postleitzahl
    Goodyear, Vereinigte Staaten· Rekrutierung
  • Ascentage Investigative Site #1062
    Verifizierte Postleitzahl
    Duarte, Vereinigte Staaten· Rekrutierung
  • Ascentage Investigative Site #1099
    Verifizierte Postleitzahl
    Irvine, Vereinigte Staaten· Rekrutierung
  • Ascentage Investigative Site #1075
    Verifizierte Postleitzahl
    La Jolla, Vereinigte Staaten· Rekrutierung
  • Ascentage Investigative Site #1100
    Verifizierte Postleitzahl
    Long Beach, Vereinigte Staaten· Rekrutierung
  • Ascentage Investigative Site #1059
    Verifizierte Postleitzahl
    Los Angeles, Vereinigte Staaten· Rekrutierung
  • Ascentage Investigative Site #1121
    Verifizierte Postleitzahl
    Sacramento, Vereinigte Staaten· Rekrutierung
  • Ascentage Investigative Site #1109
    Verifizierte Postleitzahl
    Upland, United States· Rekrutierung
  • Ascentage Investigative Site #1045
    Verifizierte Postleitzahl
    Augusta, United States· Rekrutierung
  • Ascentage Investigative Site #1110
    Verifizierte Postleitzahl
    Newnan, Vereinigte Staaten· Rekrutierung

Häufige Fragen

What is CML-CP?

CML-CP stands for Chronic Myeloid Leukemia - Chronic Phase. It's a type of blood cancer that starts in the bone marrow, and the chronic phase is usually the earlier, slower-progressing stage of the disease.

What is olverembatinib?

Olverembatinib is a new medicine being tested in this study. It's designed to treat CML by targeting specific pathways that help cancer cells grow. It's not yet approved for general use.

What is the T315I mutation?

The T315I mutation is a specific change in the genetic make-up of CML cancer cells. This change can sometimes make certain CML medicines less effective, so new treatments are needed for people with this mutation.

Werde ich wissen, welches Medikament ich bekomme?

If you are in the part of the study comparing olverembatinib and bosutinib, you will not know which medicine you are receiving. If you are in the part looking at the T315I mutation, you will receive olverembatinib.

Kann ich die Studie jederzeit verlassen?

Yes, you have the right to withdraw from the study at any point, for any reason, without it affecting your medical care.

Wie Sie mehr erfahren können

Ascentage Clinical Operations

Sprechen Sie immer mit Ihrem Hausarzt oder Spezialisten, bevor Sie sich entscheiden, an einer Studie teilzunehmen.

Interessiert daran, teilzunehmen?

Registrieren Sie Ihr Interesse

Teilen Sie Ihre Details und das Forschungsteam für "Study of Olverembatinib (HQP1351) in Patients With CML-CP… wird Sie kontaktieren, wenn Sie möglicherweise infrage kommen. Sprechen Sie immer mit Ihrem Hausarzt, bevor Sie zustimmen, teilzunehmen.

Diskussion

Community-Diskussion

Bereitgestellt von unserem Forum bei community.patient.info. Bitte seien Sie respektvoll — dies ist kein medizinischer Rat.